INTEC PHARMA LTD. UNDERWRITING AGREEMENTUnderwriting Agreement • July 16th, 2015 • Intec Pharma Ltd. • Pharmaceutical preparations • New York
Intec Pharma Ltd., a company organized and existing under the laws of the State of Israel, public company number ● (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the underwriters named in Schedule I hereto (collectively, the “Underwriters”), for whom Maxim Group LLC and Roth Capital Partners, LLC are together acting as representatives (in such capacity, the “Representatives”), an aggregate of ● Ordinary Shares (the “Firm Shares”), no par value (the “Ordinary Shares”), of the Company. The Company has granted the Underwriters the option to purchase an aggregate of up to ● Ordinary Shares (the “Option Shares”) as may be necessary to cover over-allotments made in connection with the offering. The Firm Shares and Option Shares are collectively referred to as the “Shares.”
AMENDMENT TO JOINT VENTURE FOR R&D AGREEMENTJoint Venture for R&d Agreement • July 16th, 2015 • Intec Pharma Ltd. • Pharmaceutical preparations
This amendment to Joint Venture for R&D Agreement (this “Amendment”) is entered into as of March 12, 2015, by and between Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. (“Yissum”) and Intec Pharma Ltd. (“Company”) (each to be referred to as a “Party” and together as the “Parties”).
NOTE: PORTIONS OF THIS EXHIBIT ARE THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST BY THE REGISTRANT TO THE SECURITIES AND EXCHANGE COMMISSION (“COMMISSION”). SUCH PORTIONS HAVE BEEN REDACTED AND FILED SEPARATELY WITH THE COMMISSION AND ARE MARKED...Research and License Agreement • July 16th, 2015 • Intec Pharma Ltd. • Pharmaceutical preparations • New York
This RESEARCH, OPTION AND LICENSE AGREEMENT (this “Agreement”) is entered into as of April 15, 2015 (the “Effective Date”) by and between INTEC PHARMA LTD., with offices located at 12 Hartom St., P.O.B 45219, Jerusalem 91450 (“Intec Pharma”) and BIOGEN MA INC. with offices located at 14 Cambeidge Center, Camberidge, Massachusetts, 02142 USA (“Biogen”). Each of Intec Pharma and Biogen is sometimes referred to individually herein as a “Party” and collectively as the “Parties.”
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • July 16th, 2015 • Intec Pharma Ltd. • Pharmaceutical preparations • New York
This Registration Rights Agreement (this “Agreement”) is made and entered into as of July 8, 2015 by and among Intec Pharma Ltd., an Israeli corporation (the “Company”), Gabriel Capital Management (GP) Ltd (“Gabriel”) and the other persons identified on Schedule A hereto (collectively, the “Investors” and, each individually, an “Investor”).
